Lineage Cell Therapeutics (LCTX) Depreciation & Amortization (CF) (2016 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Depreciation & Amortization (CF) of $188000.0 for Q1 2026, up 14.63% year-over-year from $164000.0 in Q1 2025, and up 1.08% quarter-over-quarter from $186000.0 in Q4 2025.
Powered by 
Analysis
Lineage Cell Therapeutics (LCTX) Depreciation & Amortization (CF) (2016 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $188000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 14.63% year-over-year to $188000.0; the TTM figure through Mar 2026 stood at $723000.0 (up 20.9% YoY), while the FY2025 annual figure was $699000.0, up 19.08% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $188000.0, up from $186000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $188000.0 in Q1 2026, with the low at $138000.0 in Q1 2023.
- The 5-year median for Depreciation & Amortization (CF) is $146000.0 (2022), against an average of $154000.0.
- The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) fell 13.79% in 2022, then gained 26.24% in 2025.
- Lineage Cell Therapeutics' Depreciation & Amortization (CF) stood at $141000.0 in 2022, then increased by 1.42% to $143000.0 in 2023, then grew by 5.59% to $151000.0 in 2024, then advanced by 23.18% to $186000.0 in 2025, then advanced by 1.08% to $188000.0 in 2026.
- Business Quant data shows LCTX's Depreciation & Amortization (CF) at $188000.0 in Q1 2026, $186000.0 in Q4 2025, and $178000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Lineage Cell Therapeutics | 270.71 Mn | 213.99 Mn | 1.07 Mn | 187,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 187,000.00 |
| Mar 31, 2026 | 188,000.00 |
| Dec 31, 2025 | 186,000.00 |
| Sep 30, 2025 | 178,000.00 |
| Jun 30, 2025 | 171,000.00 |
| Mar 31, 2025 | 164,000.00 |
| Dec 31, 2024 | 151,000.00 |
| Sep 30, 2024 | 141,000.00 |
| Jun 30, 2024 | 142,000.00 |
| Mar 31, 2024 | 153,000.00 |
| Dec 31, 2023 | 143,000.00 |
| Sep 30, 2023 | 143,000.00 |
| Jun 30, 2023 | 138,000.00 |
| Mar 31, 2023 | 138,000.00 |
| Dec 31, 2022 | 141,000.00 |
| Sep 30, 2022 | 145,000.00 |
| Jun 30, 2022 | 146,000.00 |
| Mar 31, 2022 | 150,000.00 |
| Dec 31, 2021 | 159,000.00 |
| Sep 30, 2021 | 166,000.00 |